In response to a critical funding gap affecting the NF1 research community, the Neurofibromatosis Therapeutic Acceleration Program (NTAP) has launched a new training initiative: the NF1 Basic and Translational Laboratory Scholars Program. This program is […]
Read More
Dr. Vincent Riccardi is a foundational figure in the field of neurofibromatosis (NF) research. His dedication to understanding NF1 extended beyond tumor development—he recognized the broader, systemic impact of the condition and championed a whole-person […]
Read More
Angela Hirbe, MD, Ping Chi, MD, Peter de Blank, MD, Vincent Riccardi, MD, Francis Collins, MD, Matt Steensma, MD, Ashley Cannon, PhD., Miriam Bornhorst, MD, and Verena Staedtke, MD
Read More
In this exclusive interview, Dr. Francis S. Collins, renowned geneticist and former Director of the National Institutes of Health, reflects on the impact of the Francis Collins Scholars (FCS) Program for Neurofibromatosis Type 1 (NF1) […]
Read More
Over the past ten years, the Francis Collins Scholars (FCS) Program has had a transformative impact on the careers of early-career researchers in the field of neurofibromatosis type 1 (NF1) and related disorders. In interviews […]
Read More
Baltimore, MD – In 2014, the Francis S. Collins Scholars Program (FCS) in Neurofibromatosis Clinical and Translational Research was launched to transform the landscape of NF1 research by attracting top clinician-scientists into the field. Named […]
Read MoreN Engl J Med 2020; 382:1430-1442 DOI: 10.1056/NEJMoa1912735 List of authors. Andrea M. Gross, M.D., Pamela L. Wolters, Ph.D., Eva Dombi, M.D., Andrea Baldwin, P.N.P., Patricia Whitcomb, R.N., Michael J. Fisher, M.D., Brian Weiss, M.D., […]
Read MoreA young patient with NF1 who was treated at NCI gathers with her mother and members of NCI’s Pediatric Oncology Branch. Credit: National Institutes of Health Over 30 years of NCI-led and NCI-supported research culminated […]
Read MoreInduced pluripotent stem cells have been generated for the first time from tumor cells in order to study therapies for tumors developed in patients with hereditary diseases with predisposition to cancer The study focuses on […]
Read MoreFor Release: October 2018 Development of therapies for human disease remains dependent on well-characterized and validated model systems. Slow growing histologically benign tumors such as neurofibromas are challenging to grow in typical culture conditions. As […]
Read More